We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...

Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for ...

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated multiple routes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might take to develop high-level ...

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United ...

BOSTON--(BUSINESS WIRE)--DeepCure, a leader in discovering novel therapeutics powered by AI and automation, announced today that its Inspired Chemistry™ platform had achieved a breakthrough in ...

Paxlovid does not significantly alleviate symptoms of COVID-19 compared with placebo among nonhospitalized adults, a new study published on April 3 in The New England Journal of Medicine found. The ...

The body of research on nirmatrelvir-ritonavir demonstrates a plethora of benefits in the treatment of COVID-19, and authors of a recent study identified more advantages to administering the treatment ...

Nirmatrelvir-ritonavir (Paxlovid) did not prevent people exposed to COVID-infected household members from getting infected with the virus, according to the final results of the phase II/III EPIC-PEP ...

The development of an oral anti-viral medication that could reduce COVID-19 hospitalizations and deaths in unvaccinated high-risk individuals was nothing short of game-changing and something that ...

Please provide your email address to receive an email when new articles are posted on . There are drug-drug interactions between the COVID-19 treatment ritonavir/nirmatrelvir and various classes of ...